Trial ID 20346 | Maryland Oncology Hematology Trial ID 20346 – Maryland Oncology Hematology

Trial ID 20346

Trial Information - Phase II

A PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIANíS CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Protocol ID: XPORT-MF-035

Sponsor: Karyopharm Therapeutics

Status: STAR Trial

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Myelofribrosis

Status

STAR Trial

Sponsor

Karyopharm Therapeutics

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology